6 research outputs found
Short report: zinc sulphate supplementation corrects abnormal erythrocyte membrane longâchain fatty acid composition in patients with Crohn's disease
Patients with Crohn's disease may become zincâdeficient and, in such patients, an altered metabolism of radiolabelled longâchain fatty acids has been reported. We have investigated the possible reversal by zinc supplementation of altered longâchain fatty acid profiles of red cells in Crohn's disease. Twenty patients with longâstanding Crohn's disease in clinical remission received 200 mg of zinc sulphate daily for 6 weeks. Phospholipid fatty acid profiles of washed red cells were analysed before and after zinc treatment and compared to those of 20 unsupplemented healthy controls. Plasma zinc levels in Crohn's were 72 ± 8 ÎŒg/dL before zinc treatment and increased to 114 ± 10 ÎŒg/dl after the therapy. Prior to zinc supplementation, the percentage of palmitic, stearic and oleic acids was significantly higher in Crohn's disease, while linoleic, arachidonic and nâ3 fatty acids were reduced in Crohn's disease compared to healthy controls. Zinc supplementation abolished these preâtreatment differences in redâcell longâchain fatty acid profiles but did not affect plasma fatty acid values. Further studies are needed to clarify whether these fatty acid changes can be related to the clinical course of the disease. Copyright © 1994, Wiley Blackwell. All rights reserve
Topical administration of 5-aminosalicylic acid enemas in patients with ulcerative colitis. Studies on rectal absorption and excretion
5-aminosalicylic acid (5-ASA) is a new treatment for patients suffering from ulcerative colitis but only limited information is available about its rectal absorption. We therefore studied seven patients with ulcerative colitis in remission, and five with active disease to determine acetylated and free 5-ASA plasma concentrations and urinary acetyl 5-ASA after the administration of three different types of enemas: (2 g 5-ASA/100 ml, 4 g/100 ml, and 200 ml). In patients in remission urinary acetyl 5-ASA excretion was dose and volume dependent (p<0.01; p<0.05) but this correlation was absent in active disease. Because aminosalicylates are usually eliminated through the kidney, these low values (10% in active disease and 19% in those in remission) suggest that the beneficial action may be local. Urinary recovery was significantly lower in patients with active disease (p<0.01; p<0.02). No accumulation of 5-ASA was found in plasma after repeated daily administration